Abeona Therapeutics director Mark Alvino sells $87,966 in shares By Investing.com

Mark Alvino, a director at ABEONA THERAPEUTICS INC. (), sold 15,000 shares of common stock on September 1, 2026. The transactions totaled $87,966, with shares sold at prices ranging from $5.80 to $5.9250.

Following this sale, Mr. Alvino directly holds 62,065 shares of Abeona Therapeutics common stock. The stock currently trades at $5.98, up roughly 13% year-to-date but down approximately 13% over the past year. According to InvestingPro analysis, the company appears undervalued at current levels, placing it among stocks on the most undervalued list. Investors seeking deeper insights can access a comprehensive Pro Research Report on ABEO, one of 1,400+ available on InvestingPro.

In other recent news, Abeona Therapeutics reported its second-quarter earnings for 2026, revealing a 31% increase in revenue from its lead therapy, ZEVASKYN, compared to the first quarter. Despite this growth, the company fell short of Wall Street’s expectations, posting $11.4 million in revenue against a forecast of $12.24 million. Abeona Therapeutics also reported a net loss of $20.2 million, or $0.35 per share, as it continues to expand its commercial launch and treatment-center network. These recent developments have been a focal point for investors. Additionally, the company’s shares experienced a decline following the earnings announcement. Analyst firms have been closely monitoring the situation, although specific upgrades or downgrades have not been mentioned. The company’s financial performance remains a critical area of interest for stakeholders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.